Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The improvement effect of liver dysfanction and inhibitory effect of fibrosis marker by sitagliptin or repaglinide treatment for fatty liver(liver dysfunction) patients with type2 diabetes mellitus.

Next Previous
Search
Trial Profile

The improvement effect of liver dysfanction and inhibitory effect of fibrosis marker by sitagliptin or repaglinide treatment for fatty liver(liver dysfunction) patients with type2 diabetes mellitus.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitagliptin (Primary) ; Repaglinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Jun 2016 Planned End Date changed from 31 Dec 2014 to 31 Dec 2016.
    • 10 Dec 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top